CYP2D6 Poor Metabolizer: Drugs to Avoid & What You Need to Know

What Is CYP2D6?

CYP2D6 is a gene on chromosome 22 that produces a liver enzyme belonging to the cytochrome P450 superfamily. Despite accounting for only about 2–4% of total liver CYP content, this single enzyme is responsible for the metabolism of approximately 25% of all clinically used medications. That makes it one of the most pharmacologically important genes in your entire genome.

When you swallow a pill, the CYP2D6 enzyme is often what converts that drug into its active form (activation) or breaks it down for elimination (inactivation). If your CYP2D6 enzyme works too slowly, drugs accumulate to toxic levels. If it works too fast, drugs are cleared before they can take effect. Either way, the standard dose — the one printed on the label — is wrong for you.

The problem is that CYP2D6 is one of the most polymorphic genes in the human genome. Over 100 allelic variants have been identified, and the functional impact ranges from complete enzyme absence to dramatically amplified activity. Your CYP2D6 status is inherited, permanent, and affects every prescription that passes through this enzyme for your entire life.

The Four Metabolizer Types

Based on your combination of CYP2D6 alleles, you fall into one of four metabolizer categories. Each has distinct clinical implications.

How Star Alleles Work

CYP2D6 variants are classified using “star allele” nomenclature. Each star allele represents a specific haplotype — a set of genetic changes that travel together on the same copy of the gene. You inherit one allele from each parent, giving you a diplotype (for example, *1/*4).

Each allele is assigned an activity score: 1 for normal function, 0.5 for reduced, and 0 for non-functional. Your two alleles are summed to produce a total activity score that determines your metabolizer phenotype.

A person who is *4/*4 has an activity score of 0 — a poor metabolizer with no functional CYP2D6 enzyme. A person who is *1/*10 scores 1.5 — a normal metabolizer with slightly reduced capacity. A person with *2x2/*2 (three functional copies) scores 3.0 — an ultra-rapid metabolizer. The diplotype-to-phenotype translation is standardized by the Clinical Pharmacogenetics Implementation Consortium (CPIC).

How Common Is This?

CYP2D6 variant frequencies vary dramatically across ancestral populations. Approximately 5–7% of Caucasians are poor metabolizers, most commonly due to the *4 allele. In East Asian populations, the *10 allele is found in roughly 40% of individuals, making intermediate metabolizer status far more common. In parts of East Africa and the Middle East, ultra-rapid metabolizer rates can reach 10–29% due to high frequencies of gene duplications.

Overall, approximately 6–8% of the global population carries CYP2D6 variants that significantly alter drug metabolism. That translates to hundreds of millions of people who may be receiving standard drug doses that are wrong for their genotype — most of whom have never been tested.

CYP2D6 Medication List: Drugs Affected by Metabolizer Status

The following medications have CPIC or FDA pharmacogenomic guidelines related to CYP2D6 status. For poor metabolizers, most of these drugs accumulate to higher plasma levels than intended, increasing side effects. For prodrugs (marked below), poor metabolizers get reduced therapeutic effect because the drug cannot be converted to its active form.

The Codeine Story: Why the FDA Intervened

Codeine is a prodrug. It does almost nothing on its own. The CYP2D6 enzyme converts it into morphine, which is the actual pain reliever. This conversion is the reason codeine exists as a prescription drug at all.

For poor metabolizers, codeine simply does not work. The enzyme cannot perform the conversion, so the patient gets minimal morphine and no meaningful pain relief. Doctors often respond by increasing the dose — which still does not work, because the bottleneck is enzymatic, not dose-dependent.

The codeine-CYP2D6 interaction is the most well-known example of pharmacogenomic risk, but it is not unique. The same principle applies to tramadol (also a prodrug requiring CYP2D6 activation) and to tamoxifen, where poor metabolizers produce far less of the active metabolite needed to prevent breast cancer recurrence.

What “Poor Metabolizer” Actually Means for You

If you are a CYP2D6 poor metabolizer, the clinical implications depend on whether a given drug is an active compound or a prodrug:

For ultra-rapid metabolizers, the pattern reverses. Active drugs are cleared too quickly, so standard doses have little effect and patients are often labeled as “non-responders.” Prodrugs are converted too aggressively, flooding the body with active metabolite and creating toxicity at normal doses.

CPIC Guidelines: Evidence-Based, Not Experimental

The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes freely available, peer-reviewed guidelines that translate genetic test results into specific prescribing recommendations. These are not theoretical — they are graded based on the strength of clinical evidence and are endorsed by major medical institutions.

CPIC guidelines for CYP2D6 currently cover codeine, tramadol, tricyclic antidepressants, SSRIs, ondansetron, tamoxifen, and atomoxetine, among others. Each guideline provides specific dose adjustments or alternative drug recommendations based on metabolizer phenotype.

Pharmacogenomics is not experimental or futuristic. Over 400 FDA-approved drug labels now include pharmacogenomic information. Major health systems including St. Jude Children’s Research Hospital, Vanderbilt University Medical Center, and the Mayo Clinic have implemented pre-emptive pharmacogenomic testing programs. The science is established. The gap is in getting tested.

How to Get Tested

CYP2D6 status can be determined through pharmacogenomic testing. There are several paths:

What to Do If You Are a Poor Metabolizer

A CYP2D6 poor metabolizer result is not a diagnosis — it is pharmacogenomic information that helps your doctor prescribe more safely. Here is what to do with it:

The Bottom Line

CYP2D6 is a single gene, but it touches roughly one in four prescription drugs. If you are among the 5–10% of the population with poor or ultra-rapid metabolizer status, standard drug dosing is wrong for you — and you may have already experienced the consequences without understanding why.

Unlike most genetic risks, pharmacogenomic information is immediately actionable. You do not need to wait for a disease to develop. You do not need lifestyle changes or long-term monitoring. You need your doctor to know your metabolizer status before writing the next prescription.

The test costs less than a single emergency room visit for an adverse drug reaction. The information lasts a lifetime. And for millions of people, it is already sitting in a DNA file they downloaded years ago and never fully analyzed.